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1 Sorbonne Université, INSERM, CNRS, Centre d’Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France,
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Hepatocyte invasion by Plasmodium sporozoites represents a promising target for
innovative antimalarial therapy, but the molecular events mediating this process are still
largely uncharacterized. We previously showed that Plasmodium falciparum sporozoite
entry into hepatocytes strictly requires CD81. However, CD81-overexpressing human
hepatoma cells remain refractory to P. falciparum infection, suggesting the existence of
additional host factors necessary for sporozoite entry. Here, through differential
transcriptomic analysis of human hepatocytes and hepatoma HepG2-CD81 cells, the
transmembrane protein Aquaporin-9 (AQP9) was found to be among the most
downregulated genes in hepatoma cells. RNA silencing showed that sporozoite
invasion of hepatocytes requires AQP9 expression. AQP9 overexpression in
hepatocytes increased their permissiveness to P. falciparum. Moreover, chemical
disruption with the AQP9 inhibitor phloretin markedly inhibited hepatocyte infection. Our
findings identify AQP9 as a novel host factor required for P. falciparum sporozoite
hepatocyte-entry and indicate that AQP9 could be a potential therapeutic target.
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INTRODUCTION
Of the protozoan parasites of humans, Plasmodium falciparum is the deadliest, accounting for an
estimated 228 million cases of malaria and causing 405 000 deaths in 2018 (WHO | World malaria
report 2018). After being inoculated in the skin of a host during the bite of an infected Anopheles
mosquito, the sporozoite form of the parasite is quickly conveyed by the blood to the liver. Once
there, it is sequestered via interactions with heparan sulphate proteoglycans (HSPGs), crosses the
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endothelial barrier, and then migrates through several
parenchymal cells before invading a hepatocyte by forming a
membrane-bound compartment called the parasitophorous
vacuole membrane (PVM), where it can develop and multiply
to form merozoites that initiate the pathogenic erythrocytic cycle
(Mota et al., 2001).
Sporozoite entry into hepatocytes is a highly complex process
that involves coordinated interaction of sporozoite and host
factors for initiation of infection, which may offer a multitude
of promising therapeutic targets (Dundas et al., 2019). Currently,
two major host cell surface proteins are well known to be
involved in sporozoite invasion, the tetraspanin CD81 and the
scavenger receptor class B type1 (SR-BI) (Silvie et al., 2003;
Rodrigues et al., 2008; Yalaoui et al., 2008a), but how they
interact with specific parasite ligands remains largely unknown
(Silvie et al., 2007). Moreover, the molecular events involved in
sporozoite invasion are further complicated because they depend
on the plasmodial species and the host cell type (Risco-Castillo
et al., 2014). Indeed, CD81 is essential for P. falciparum and P.
yoelii sporozoite invasion (Silvie et al., 2003) but is not required
by P. vivax, which depends only on SR-BI. On the other hand,
SR-BI is not required for P. falciparum and P. yoelii infections
(Manzoni et al., 2017). However, P. berghei sporozoites can enter
cells alternatively via either CD81 or SR-BI (Manzoni et al.,
2017). The choice of route by which sporozoites invade
hepatocytes has been shown to be determined by the parasite
6-cysteine domain protein P36 in a species-specific manner
(Manzoni et al., 2017). In addition, SR-BI has been found to be
essential for subsequent parasite development inside hepatocytes
but not CD81 (Silvie et al., 2003; Rodrigues et al., 2008). Most
recently, another host factor, aquaporin 3 (AQP3), which is a
water and glycerol channel belonging to the aquaglyceroporin
subfamily, has been implicated in the maturation of parasites
after invasion (Posfai et al., 2018; Posfai et al., 2020).
P rev ious s tud i e s have shown tha t the human
hepatocarcinoma HepG2 cells express SR-BI but not CD81,
and as a consequence, they support infection by P. berghei but
not by P. falciparum or P. yoelii sporozoites (Silvie et al., 2006b;
Manzoni et al., 2017). Interestingly, ectopic expression of CD81
in HepG2 cells is sufficient to confer susceptibility to P. yoelii but
not to P. falciparum sporozoites (Silvie et al., 2006b), implying
the existence of additional host factors that are critical for P.
falciparum infection.
The aim of this study was to identify host proteins required
for successful infection of human hepatocytes by P. falciparum
sporozoites. The approach adopted was that of a differential
transcriptome analysis of naturally permissive human
hepatocytes versus non-permissive hepatoma HepG2-CD81
cells. Among the most downregulated genes in the non-
permissive cells, we focused on that coding for aquaporin-9
(AQP9), a water and glycerol channel previously shown to be
involved in mice susceptibility to P. berghei blood stage infection
(Liu et al., 2007). The contribution of AQP9 to the Plasmodium
liver stage of P. falciparum, P. yoelii and P. berghei was
investigated using primary human hepatocytes, human
hepatoma cells and primary murine hepatocytes.
MATERIALS AND METHODS
Ethics Statement
Human hepatocytes were isolated from liver segments taken
after oral informed consent was obtained from adult patients
undergoing partial hepatectomy as part of their medical
treatment (Service de Chirurgie Digestive, Hépato-Bilio-
Pancréatique et Transplantation Hépatique, Hôpital Pitié-
Salpêtrière, Paris, France). The collection and use of this
material for the purposes of the study presented here were
undertaken in accordance with French national ethical
guidelines under Article L. 1121-1 of the ‘‘Code de la Santé
Publique’’. Given that the tissue samples were classed as surgical
waste, they were used anonymously. Moreover, because they
were not in any way genetically manipulated, article L. 1211-2
stipulates that their use for research purposes is allowed provided
that the patient does not express any opposition to this to the
surgeon prior to surgery after being informed of the nature of the
research in which they might be potentially employed. The
collection and use of this material were furthermore approved
by the Institutional Review Board (Comité de Protection des
Personnes) of the Centre Hospitalo-Universitaire Pitié-
Salpêtrière, Assistance Publique-Hôpitaux de Paris, France. All
animal care and procedures were carried out in strict accordance
with the recommendations of the Guide for the Care and Use of
Laboratory Animals of the European Union “European directive
86/609/EEC”. The protocol was approved by the Ethics
Committee for Animal Experiments of University Pierre et
Marie Curie, Paris 6, France (Permit Number: 75-1087).
RNA Isolation, Microarray Protocol and
Differential Analysis of Transcriptomes
Three sets of human primary hepatocytes (Supplementary
Table 1) were cultured for one week in a differentiation
maintenance medium (complete medium for hepatocyte
culture supplemented with 2% DMSO) (Isom et al., 1985).
Hepatoma-derived HepG2-CD81 cells (Silvie et al., 2006b)
from three different cultures were grown to subconfluence in
75 cm² flasks. Cells were lysed with TRIzol (Invitrogen, Life
Technologies), and RNA was purified according to the
manufacturer’s instructions. RNA was equally purified from
1 g of human liver for use as a reference in all the microarray
hybridizations. RNA concentration and purity were assessed
using a NanoDropND-1000 Spectrophotometer (Thermo
Scientific) and the Agilent 2100 Bioanalyser.
Transcriptomes of P. falciparum permissive human
hepatocytes (HHs) and refractory HepG2-CD81 hepatoma
cells (HCs) were analysed using a human 1A oligoarray kit
(pangenomic human 22K DNA microarrays from Agilent
Technologies, Les Ulis, France). Cyanine-labelled cDNA probes
were synthesized from 20 mg of HH, HC, or total liver RNA using
a CyScribe Post-Labelling kit (GE Healthcare Life Sciences,
Vélizy, France). cDNA probes synthesized from cell RNAs
were labelled with cyanine 3 (Cy3), while probes synthesized
from the liver reference RNA were labelled with cyanine 5 (Cy5).
Cy3- and Cy5-labelled probes were then co-hybridized to spots
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on the same microarray. Signals were extracted using a Genepix
4000B scanner (Axon Instruments) and Genepix Pro 6.0
software and normalized with VARAN software (http://www.
bionet.espci.fr/varan/), allowing calculation of the HH/HC
intensity ratio for each targeted gene spotted on the microarray
as the ratio of (HH/reference intensity ratio) versus
(HC/reference intensity ratio). All microarray procedures were
performed in accordance with the manufacturer’s instructions.
The CD81 synthetic oligonucleotide probe used here is
complementary to the endogenous 5’-untranslated region of
wild type CD81 but not to the ectopic CD81 expressed by the




Primary human hepatocytes were isolated from healthy parts of
the liver fragments as previously described (Yalaoui et al., 2008a).
Primary mouse hepatocytes were isolated as previously described
(Yalaoui et al., 2008a) from AQP9-/- mice backcrossed onto a
C57BL/6J background and their AQP9+/+ littermate controls
aged 7 to 10 weeks and gender matched (Rojek et al., 2007).
These mice were kindly provided by Pr. S. Nielsen (Aarhus
University, Aarhus, Denmark) and Pr. M. Amiry-Moghaddam
(University of Oslo, Oslo, Norway). Human and mouse
hepatocytes were seeded at a density of 8 × 104 cells and 4×
104 cells, respectively, in 96-well microplates precoated with rat
tail collagen I (Becton Dickinson) and cultured at 37°C in 5%
CO2 in William’s E medium (Gibco, Life Technologies, Saint
Aubin, France) supplemented with 2% penicillin-streptomycin,
1% sodium pyruvate, 1% L-glutamine, 1% insulin-transferrin-
selenium, 1% non-essential amino acids (solutions for cell
culture, Gibco) and 10% foetal bovine serum (FBS, Gibco). For
human hepatocyte, the culture medium was also supplemented
with 10–7 M dexamethasone (Sigma) and 2% DMSO. HepG2-
CD81 (Bartosch et al., 2003; Silvie et al., 2006b) human
hepatoma cells were cultured in DMEM (Gibco) supplemented
with 10% FBS, 1% glutamine and 1% penicillin-streptomycin
(Gibco). HepaRG human hepatoma cells, a gift from Pr. C.
Guillouzo (INSERM, Rennes, France), were cultured in
William’s E medium (Gibco) supplemented with 1% penicillin-
streptomycin, 1% L-glutamine, insulin (5 μg/ml), 5 × 10-5 M
hydrocortisone and 10% FBS (Thermo Scientific, Villebon-sur-
Yvette, France). Mouse and human hepatocytes as well as human
hepatoma cells were cultured for at least 24 hours before
further studies.
Plasmodium Parasites
and In Vitro Infection
P. yoelii (265BY strain), P. berghei (PbGFPCON, ANKA strain)
(Franke-Fayard et al., 2004) and P. falciparum (NF54 strain)
sporozoites were obtained by dissection of salivary glands from
infected Anopheles stephensimosquitoes bred and infected in the
insectary facilities of UMRS 945 (Paris, France) for rodent
Plasmodium-infected mosquitoes and the Department of
Medical Microbiology, Radboud University (Nijmegen,
Holland) for P. falciparum-infected mosquitoes. Infection
assays were performed in 96-well plates. Cells were inoculated
with 3 x 104 P. falciparum or 2 x 104 P. berghei or P. yoelii
Plasmodium sporozoites per well and then centrifuged for
10 min at 2000 rpm to allow fast parasite sedimentation onto
the target cells. After 3 hours at 37°C/5% CO2, thus allowing
sporozoite penetration into hepatocytes, cultures were washed
and further incubated in fresh medium for 2 or 4 days (for P.
yoelii and P. berghei or P. falciparum, respectively) until
quantification of EEFs or directly fixed in PFA for
quantification of parasite entry.
Gene Knockdown Using Small
Interfering RNAs
For gene knockdown, we used small double-stranded RNA
oligonucleotides (siRNAs) targeting human CD81 (sihCD81;
5’- GCA CCA AGT GCA TCA AGT A -3’), human AQP3
(AQP3_5 siRNA from Qiagen HP GenomeWide), human AQP9
(sihAQP91; 5’-CTG CTG ATC GTG GGA GAA A-3’ and
sihAQP9s2 to 5 corresponding respectively to siRNAs from
Qiagen HP GenomeWide - AQP9_1 HP siRNA; AQP9_2 HP
siRNA; AQP9_4 HP siRNA; AQP9_5 HP siRNA), and hCD92
(sihCD92; 5’- AAG GCA AGA ACT GAA AAC T -3’), used as a
negative control. Primary hepatocytes were transfected with 30
nM siRNA in 96-well microplates using Lipofectamine RNAi
MAX (Invitrogen) according to the manufacturer ’s
recommendations. HepaRG cells (5 × 106 cells in 400 μl of
RPMI) were transfected with 200 pmol of siRNA via
electroporation (300 V, 500 μF) (Silvie et al., 2006a) using a
Gene Pulser apparatus (Bio-Rad,Ivry, France). siRNA-
transfected hepatoma cells or hepatocytes were then cultured
for 48 hours before mRNA expression analysis or for 72 hours




The lentiviral constructs pTRIP-CMV-hAQP9 DU3 and pTRIP-
CMV-hCD81 DU3 were generated via gateway recombination
cloning (Invitrogen). Briefly, hAQP9 and hCD81 coding
sequences were PCR amplified and cloned into a pENTR/D/
TOPO plasmid (Invitrogen) to generate entry clones. LR clonase
II recombination was performed using the entry clones and the
pTRIP-CMV-rfa Gateway DU3 destination vector as described
previously (Russ et al., 2008). The pTRIP-CMV-GFP DU3 vector
(Castaing et al., 2005) was used as a control. Lentiviral vector
stocks were produced by transient transfection of 293T cells with
the p8.91 encapsidation plasmid (Zufferey et al., 1997), the VSV
glycoprotein-G encoding pHCMV-G plasmid (Yee et al., 1994),
and the pTripDU3 lentiviral vector as previously described
(Zennou et al., 2000). Supernatants were treated with DNAse I
(Roche Diagnostics) prior to ultracentrifugation, and the
resulting pellet was resuspended in PBS, separated into aliquots
and frozen at 80°C until use. Primary human hepatocytes and
hepatoma cells were transduced through addition of a 1:1000
concentrated lentiviral preparation. After an incubation period
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of three hours, the cells were washed. Three days later, the
cultures were processed for protein expression analysis as
described in western blotting procedures or infected with
sporozoites and cultured for four days until exo-erythrocytic
forms (EEFs) quantification to evaluate hepatocyte
permissiveness to Plasmodium infection.
Quantification of hAQP9 and hCD81
Transcripts via Real-Time PCR
RNA extractions were performed with a PureLink RNA Mini Kit
(Ambion, Life Technologies) according to the manufacturer’s
recommendations. DNase treatment (PureLink DNase Set;
Ambion, Life Technologies) was performed during the
extraction. The quality and purity of RNAs were assessed with
the Agilent 2100 Bioanalyser. Reverse transcription was realized
with a SuperScript VILO cDNA Synthesis Kit (Invitrogen)
according to the manufacturer’s instructions, using 1 μg of
RNA in a 20 μL final volume and duplicates for all samples.
Quantitative real-time PCRs (qPCRs) were carried out using the
SYBR Green method (SYBR GreenER qPCR SuperMix
Universal, Invitrogen) with a MX3005P qPCR System (Agilent
Technologies). The volume of cDNA used was equivalent to 100
ng of RNA per reaction, and the primers were used at a final
concentration of 200 nM. Primer pairs based on the cDNA
sequence were specifically designed for hAQP9 (5 ’-
ttgcaacatacccagctccgtatc-3’ and 5’-accaaagggcccactacaggaat-3’)
and for hCD81 (5 ’-.tcatcctgtttgcctgtgaggt-3 ’ and 5 ’-
tgaggtggtcaaagcagtcagt-3’). All samples were run in duplicate
with the two different cDNAs synthesized, and gene expression
data were normalized according to the level of TBP (TATA box-
binding protein) (Ceelen et al., 2011).
Protein Expression Analysis via Western
Blotting and Cell Immunofluorescence
Primary human hepatocytes were lysed at 4°C for 30 minutes in
30 mM Tris (pH 7.4), 150 mM NaCl, 0.02% NaN3, protease
inhibitors (PMSF, INH) and 1% Triton X-100. CD81 and AQP9
expression was analysed via western blotting using a mouse anti-
hCD81 mAb (1:1000) and a mouse anti-m/hAQP9 mAb (G3,
Santa Cruz) (1:100), respectively, followed by a goat anti-mouse
Alexa Fluor 680 conjugate (Molecular Probes, Life Technologies)
(1:15000). Monoclonal mouse anti-tubulin (Abcam) (1:5000)
was used as a standard. Data were acquired and quantified
with an Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE).
Quantification of hCD81 and AQP9 expression at the surface
of human hepatocytes was performed as previously described for
murine hepatocytes (Yalaoui et al., 2008a). Cells were washed
with PBS, and immunolabelled for human AQP9 using a goat
anti-hAQP9 (C18, Santa Cruz) antibody and a donkey anti-goat
IgG-Alexa 488 conjugate antibody (Molecular Probes). CD81
was labelled with a mouse anti-hCD81 antibody (TS81, provided
by Dr. E. Rubinstein, INSERM, Villejuif, France) and revealed
with donkey anti-mouse IgG-Alexa 568 (Molecular Probes). Cell
density was evaluated with diamidino-phenyl-indole (DAPI,
Sigma) and used to normalize CD81 expression. Fluorescence
intensity was acquired with a Flexstation Universal Microplate
Reader (Molecular Devices, St Grégoire, France).
Quantification of Parasite Infection or
Invasion via Immunofluorescence
After fixation of cultures with cold methanol, EEFs were
identified using anti-HSP70 serum, prepared from mice
immunized with a recombinant HSP70 protein (a gift from Pr.
D. Mattei, Institut Pasteur, Paris, France), stained with an Alexa
488-conjugated or Alexa Fluor 680-conjugated goat anti-mouse
immunoglobulin (Molecular Probes) and counted under a
fluorescence microscope or using the Odyssey Infrared
Imaging System as described previously (Gego et al., 2006).
Nuclei were stained with 1 mg/ml DAPI. Quantification of
parasite entry was carried out using double immunostaining
with the appropriate mouse monoclonal anti-CSP antibody for
P. falciparum CSPP. falciparum and P. yoelii (CSPP. yoelii) (Dr. Y.
Charoenvit, Naval Medical Research Center; Silver Spring, MD),
or a TRAP antibody for P. berghei (Dr. A. Crisanti, Imperial
College, London, UK), thus allowing discrimination of
intracellular and extracellular sporozoites, as previously
described (Rénia et al., 1988; Silvie et al., 2002).
Sporozoite Cell Traversal Assay
Hepatocytic cell traversal was analysed using a dextran
incorporation FACS assay (Prudêncio et al . , 2008).
Immediately after electroporation in the presence of siAQP9,
siCD81, or siCD92, HepaRG cells were plated and cultivated in a
25 cm2 culture flask at 37°C/5% CO2. Forty-eight hours later, the
cells were trypsinized for direct mRNA expression analysis or
seeded in 48-well plates (8 x104 cells/well) for a cell traversal
assay. After 24 hours, they were incubated with 105 P. yoelii or P.
berghei sporozoites for 2 hours or with 105 P. falciparum
sporozoites for 3 hours in the presence of rhodamine-dextran
lysine fixable (10000 MW, Molecular Probes). After washing, the
cells were trypsinized, fixed with 1% glutaraldehyde and analysed
via FACS using an LSR Fortessa flow cytometer (BD
Biosciences); 104 cells were analysed (van Schaijk et al., 2008).
Infection Inhibition Assay With the AQP9
Inhibitor Phloretin
To assess the function of AQP9 in Plasmodium parasite
infection, we tested the effect of phloretin (Sigma, Saint
Quentin Fallavier, France), an inhibitor that restricts the solute
permeability of AQP9 (Tsukaguchi et al., 1998; Yang and
Verkman, 2002; Liu et al., 2007), on infection of human
primary hepatocytes by P. falciparum. Phloretin was co-
incubated with the sporozoites in the first 2 hours of the
invasion step. Thereafter, the cells were incubated with fresh
complete medium for three additional days until EEF
quantification. Phloretin concentrations up to 500 mM were
tested because this concentration has previously been shown to
inhibit 60% of urea and glycerol transport (Tsukaguchi et al.,
1998) and to not affect rat hepatocyte viability (Mosmann, 1983;
Huebert et al., 2002). Using an MTT toxicity assay (Mosmann,
1983), we assessed that phloretin was not toxic to primary
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human hepatocytes under the assay conditions (Supplementary
Figure 1). We also assessed that phloretin was not toxic on
Plasmodium sporozoites preincubated with different
concentrations of phloretin (Supplementary Figure 2).
Data Analysis
GraphPad Prism 7 statistical Software (GraphPad. Software, San
Diego, CA, USA) was used for data analysis and graphing. All
values were expressed as means and standard deviations (SD). A
p-value of 0.05 or less was considered as statistically significant.
RESULTS
Comparative Transcriptomics of
Plasmodium falciparum Permissive and
Non-Permissive Hepatocytes Identified
AQP9 as a Candidate Host Protein
Involved in Sporozoite Invasion
To identify novel host factors and further understand human
hepatocyte susceptibility to P. falciparum sporozoite invasion, we
performed differential transcriptomic analysis of naturally P.
falciparum-permissive human hepatocytes (HHs) and
refractory human hepatoma HepG2-CD81 cells (HCs) using
microarray technology. Only genes downregulated in non-
permissive hepatoma cells were taken into account. Our results
showed that a total of 276 genes were downregulated in non-
permissive hepatoma cells compared to the permissive
hepatocytes, with HH/HC ratios higher than 3. A list of the
top 30 downregulated genes with the highest ratios is presented
in (Supplementary Table 2). As expected, CD81 (with an HH/
HC ratio of 14.7) was found to be among the most
downregulated genes in hepatoma cells (Figure 1A and
Supplementary Figure 3A). It should be noted that the CD81
cDNA probe used on the DNA chips was designed to detect only
endogenous CD81 mRNA but not ectopic CD81. SR-BI (HH/
HC=6) was also found amid the downregulated genes in
hepatoma cells (Figure 1A and Supplementary Figure 3A). In
contrast, the expression ratio of the irrelevant CD9 gene (HH/
HC=1.06), which is known as not involved in hepatocyte
permissiveness to Plasmodium infection (Yalaoui et al., 2008b),
was not changed (Figure 1A and Supplementary Figure 3A).
From evaluation of each candidate gene, AQP9 which belongs
to the aquaglyceroporin subfamily, a transmembrane channel
protein that conducts water and glycerol (Liu et al., 2007), was
selected for functional investigations, because it was among the
most downregulated genes in the non-permissive HepG2 cells
(Figure 1A and Supplementary Figure 3A), and evidence from a
previous study showed it to be involved in mouse susceptibility to
P. berghei blood stage infection (Liu et al., 2007). Interestingly,
another aquaglyceroporin, AQP3, which was reported to be
involved in P. berghei development within human hepatoma
cells and in P. vivax development within human primary
hepatocytes but is not essential for sporozoite invasion (Posfai
et al., 2018; Posfai et al., 2020), was not found to be significantly
differentially expressed between the two cell types (HH/HC ratio
of 2.3) (Figure 1A). The relatively high AQP9 gene expression in
primary hepatocytes was further confirmed in hepatocytes isolated
from 4 additional donors using qPCR (Figure 1B; Supplementary
Table 1). The expression of other aquaporin genes was not or was
only moderately downregulated (Figure 1C and Supplementary
Figure 3B). Moreover, immunofluorescence experiments showed
that the drastic downregulation of the AQP9 transcript in HepG2-
CD81 cells was accompanied by a near total lack of protein
expression (Figure 1D). Overall, as a membrane-bound protein
highly expressed in infection-permissive cells and almost silent in




FIGURE 1 | AQP9 and CD81 are expressed at higher levels in P. falciparum
permissive human hepatocytes than in refractory hepatoma cells. (A)
Transcriptomes of human hepatocytes (HHs) and human hepatoma HepG2-
CD81 cells (HCs) were analysed using a 22K pan-genomic human oligo
microarray (Agilent Technologies). AQP9, CD81, AQP3 and CD9 gene
expression levels are presented as average log2 gene ratios in HH/HC. (B)
RT-qPCR analysis of AQP9 mRNA expression in 4 sets of HHs and in HCs.
Variations in transcript levels were calculated after normalisation to expression
of the TBP gene and are presented relative to the AQP9 mRNA level in HH1.
(C) Relative gene expression of aquaporins 1 to 12B in HHs from 3 donors
and HCs is presented as the mean % of the AQP9 gene expression level in
HHs, determined with the 22K pan-genomic human oligo microarray. (D)
Immunofluorescence analysis of CD81 and AQP9 expression on HHs (upper
panel) and HCs (lower panel). Cells were fixed, permeabilized, and incubated
with a mixture containing a mouse monoclonal antibody against human CD81
and human AQP9 antibody and reacted with the appropriate secondary
antibodies conjugated to Alexa 568 and Alexa 488, respectively. The white
scale bar represents 100 µm.
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hepatocyte AQP9 is a candidate protein that could be involved in
sporozoite entry into cells.
Aquaporin-9 Is Required for Efficient
P. falciparum Sporozoite Entry Into
Human Hepatocytes
To investigate the potential role of AQP9 in human hepatocyte
infection by P. falciparum sporozoites, we performed AQP9 gene
silencing using five smalls interfering RNAs (siRNAs). These
siRNAs were first tested for their ability to ablate AQP9 gene
expression in hepatocytes (Supplementary Figure 5A). sihCD92
and sihCD81 were used as negative and positive controls,
respectively. Gene silencing procedure as well as sihCD92 which
are routinely used in our laboratory have no impact on
Plasmodium infection. Next, using western blotting and
quantitative immunofluorescence, we confirmed that siAQP9
does not affect CD81 protein levels (Supplementary
Figures 5A, B). Microscopic observation of the cultures
transfected with either sihAQP9, sihCD81 or sihCD92 showed
no obvious morphological alteration of the cells nor of the cell
layer integrity (Supplementary Figure 6). Finally, we checked the
efficiency of the five siRNAs in blocking sporozoite infection of
hepatocytes (Supplementary Figure 5C). Silencing with
sihAQP91,3,5 resulted in an ~70% reduction in hepatocyte
permissiveness to P. falciparum compared to the control
sihCD92-treated hepatocytes. This reduction was similar to that
obtained with sihCD81. sihAQP94 caused an ~35% reduction in
hepatocyte permissiveness, while sihAQP92 had no effect. The
reduction in hepatocyte infectivity observed with sihAQP9s was
proportional to the inhibition ofAQP9 expression. Together, these
results show that AQP9 and CD81 are individually required for
Plasmodium infection but that neither is able to compensate for
silencing of the other. We choose siAQP91 among the 3 siRNA
(siAQP9 1,3 and 5) showing a potent and comparable silencing of
AQP9 protein to be used for the rest of our experiments.
To further define the role of AQP9, we investigated its specific
contribution to sporozoite entry into hepatocytes. Hepatocytes
were inoculated with P. falciparum sporozoites three days after
transfection, and their entry was evaluated by double
immunostaining three hours post-sporozoite infection (Rénia
et al., 1988; Silvie et al., 2002). The entry of parasites into
sihAQP9- and sihCD81-treated hepatocytes was decreased by
90% and 92%, respectively, compared to sihCD92-treated cells
(Figure 2A and Supplementary Figure 7A), and this inhibitory
effect was similar to that observed for infection efficiency. In
contrast, AQP3 gene silencing did not affect Plasmodium
sporozoite infection or entry (Figure 2A and Supplementary
Figure 7A), corroborating results obtained elsewhere (Posfai
et al., 2018).
We then examined whether AQP9 overexpression might
improve cell permissiveness to P. falciparum sporozoite
infection, as overexpression of CD81 in hepatocytic cell lines
did for rodent Plasmodium species (Silvie et al., 2006b). To this
end, we transduced human hepatocytes that naturally express
endogenous CD81 and AQP9 with a lentiviral vector allowing
expression of CD81 or AQP9, and then cultured the hepatocytes
for three days prior to Plasmodium sporozoite infection. Cells
transduced with a vector encoding the irrelevant GFP protein
were used as a control (GFP expression in liver cells was
previously reported to not alter Plasmodium infection
efficiency (Yalaoui et al., 2008b)). Overexpression of AQP9 (as
assessed by western blotting, Supplementary Figure 8) induced
a two-fold increase in hepatocyte permissiveness to P. falciparum
infection compared with GFP-transduced hepatocytes,
comparable to that of CD81 (Figure 2B). Pharmacologic
inhibition of AQP9 by phloretin during the first two hours of
A B C
FIGURE 2 | Human hepatocyte permissiveness to P. falciparum sporozoite infection depends on AQP9 expression. (A) Hepatocytes were transfected with sihRNAs
and tested for their permissiveness to P. falciparum sporozoite infection: sihCD92-, sihCD81-, sihAQP91- and sihAQP3-transfected human hepatocytes were
infected three days after transfection with P. falciparum sporozoites and cultured for 3 hours to evaluate sporozoite entry via double immunostaining for PfCSP
protein (grey bars) or for four days to evaluate cell infection after immunolabelling of EEFs using HSP70 antibody (black bars). Sporozoite and EEF numbers are
expressed as a percentage of those in sihCD92-transfected control hepatocytes. *p = 0.0006. (B) Hepatocytes overexpressing CD81 or AQP9 were tested for their
permissiveness to P. falciparum infection: hepatocytes transduced with a lentiviral vector expressing GFP protein, as a control, hCD81, or hAQP9 were infected three
days later with sporozoites and cultured for four days until EEF quantification. EEF numbers are expressed as a percentage of those in GFP-transduced control
hepatocytes. The mean schizont numbers per well in controls of three independent experiments were 141, 203, and 314. *p = 0.05. (C) Hepatocytes were treated
for the first two hours following sporozoite inoculation with three doses of phloretin. Hepatocytes were then washed and incubated with fresh complete medium for
three additional days until EEF quantification. EEF rates are relative to those in untreated hepatocytes. *p = 0.0009. All analyses were carried out in triplicate wells,
and the results are expressed as the mean ± standard deviation. p values were determined by Mann-Whitney U test.
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hepatocyte co-incubation with sporozoites resulted in a
significant reduction in hepatocyte infection in a dose-
dependent manner (Figure 2C). We also found that cell
traversal of P. falciparum sporozoites was not affected by either
CD81 or AQP9 silencing (Supplementary Figure 9A).
Since AQP9 RNA silencing induced a major, but incomplete,
inhibition of P. falciparum infection, with 10 to 30% residual
development of liver schizonts, we could assess whether AQP9
might play a role in the maturation of the parasite. SihAQP91-
treated human hepatocytes infected by P. falciparum sporozoites
were labelled four days post-inoculation with an anti-PfHSP70
antibody in order to measure the size of the schizonts.
Fluorescence microscopy analysis revealed that schizont
diameters were similar in sihCD92, sihCD81 and sihAQP91-
treated hepatocytes (Supplementary Figure 10A).
Taken together, these data clearly provide evidence that AQP9
expression is important for P. falciparum sporozoite entry into
human hepatocytes but have no influence on parasite development
at the liver stage. Interestingly, the magnitude of the effect of AQP9
silencing in human hepatocytes on infection by P. falciparum, either
on parasite entry or on the number of schizonts, is comparable to
that of CD81 silencing. Similarly, both AQP9 overexpression and




FIGURE 3 | Hepatocyte permissiveness to rodent parasites differentially depends on AQP9 according to parasite/host cell combinations. (A) sihRNA-transfected
human hepatocytes (HHs) were infected with sporozoites three days post-transfection and cultured for two days until EEF quantification. EEF values are expressed
as a percentage of those in control sihCD92-transfected hepatocytes. *p = 0.0001. (B) Three days post lentiviral transduction, HHs overexpressing GFP protein,
hCD81, or hAQP9 were cultured for two days until EEF quantification. EEF numbers are expressed as a percentage of those in control GFP-transduced hepatocytes.
*p = 0.0079. (C, D) Primary hepatocytes isolated from wild-type (WT) and AQP9 knockout (AQP9-/-) mice were infected with P. berghei or P. yoelii. Sporozoite cell
entry was evaluated 3 h post-infection using double immunostaining (C), whereas EEF quantification was performed after 48 h of culture (D). Penetration rates and
EEF numbers are expressed as a percentage of those in control WT hepatocytes. *p = 0.05; **p = 0.0018; ***p = 0.0004. The results are expressed as the mean ±
standard deviation. p values were determined by Mann-Whitney U test.
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The Rodent Parasites P. yoelii and
P. berghei Differentially Depend on
AQP9 for Infection of Liver Cells
We further extended our experiments to study liver infection by
the rodent malaria parasites P. yoelii and P. berghei. Given that
the requirement for host proteins that confer permissiveness to
Plasmodium infection may differ according to the species of the
target cell (Silvie et al., 2007) and that P. yoelii and P. berghei
sporozoites are capable of infecting human hepatocytes in vitro
(Silvie et al., 2006b), the role of AQP9 was investigated in
infection of human hepatocytes by these rodent Plasmodium
species. The permissiveness of sihCD81- and sihAQP91-treated
human hepatocytes to P. berghei infection was reduced by~79%
and ~92%, respectively. As expected, silencing of CD81 reduced
P. yoelii infection by ~87%, but surprisingly, silencing of AQP9
did not affect P. yoelii infection (Figure 3A and Supplementary
Figure 7B). In fact, the dramatic effect of AQP9 silencing on
infection by P. berghei was also somewhat unexpected, because it
is well known that human HepG2 hepatoma cells can be readily
infected by this parasite, despite undetectable AQP9 expression.
This paradox was further investigated in HepaRG cells that
express AQP9. P. berghei infection of these cells was markedly
decreased by AQP9 RNA silencing (Supplementary
Figures 11A, B), which suggests that this parasite uses AQP9-
dependent pathways to invade human liver cells naturally
expressing AQP9 but is able to use alternative pathways in
hepatoma cells that do not express AQP9 (see Table 1). CD81
or AQP9 overexpression in human hepatocytes transduced with
CD81- or AQP9-expressing lentiviral vectors led to an increase
in the number of liver schizonts in each rodent species
(Figure 3B). Finally, the availability of AQP9 knockout mice
prompted us to test permissiveness of primary hepatocytes
isolated from wild-type or AQP9 knockout mice to rodent
Plasmodium sporozoites. The total lack of AQP9 resulted in a
reduction in hepatocyte permissiveness to P. berghei and P. yoelii
infection by ~77% and ~34%, respectively (Figure 3C).
Sporozoite entry was reduced by ~69% and ~30% for P.
berghei and P. yoelii sporozoites, respectively (Figure 3D).
Similar to P. falciparum, AQP9 silencing had no effect on cell
traversal (Supplementary Figure 9B). P. berghei schizont
diameters measured two days post-infection were similar in
AQP9-knockout and wild type hepatocytes (Supplementary
Figure 10B) thus confirming that AQP9 is not involved in
parasite development at the liver stage.
Altogether, these results indicate that P. berghei and P. yoelii
display differential dependence on AQP9 for entry into
hepatocytes. Indeed, P. yoelii invasion is found to not be or be
poorly AQP9-dependent, whereas for P. berghei, invasion
depends mainly on AQP9, at least in human liver cells that
express this protein.
DISCUSSION
The first multiplicative stage of malaria parasites within their
human host occurs exclusively in the hepatocyte in vivo, and this
development can also be obtained in vitro. It is interesting that
CD81-expressing human hepatoma HepG2 cells are permissive
to productive infection by sporozoites of the rodent parasites P.
berghei and P. yoelii, but not to productive infection by P.
falciparum (Silvie et al., 2006a). This differential susceptibility
was exploited to search for proteins responsible for the exclusive
permissiveness of human hepatocytes to P. falciparum
sporozoites. Comparison of the transcriptome of human
hepatocytes with that of human hepatoma HepG2-CD81 cells,
which do not support P. falciparum sporozoite infection, led to
identification of genes whose expression is downregulated in
hepatoma cells. We focused our functional studies on AQP9, a
membrane protein already suspected to be involved in the
virulence of the rodent parasite P. berghei (Liu et al., 2007) and
whose gene expression was one of those most downregulated in
hepatoma cells. Our results demonstrate that AQP9 is required
for efficient P. falciparum sporozoite entry into human
hepatocytes. Furthermore, we found that the rodent parasites
P. yoelii and P. berghei differentially depend on AQP9 and that
this difference varies depending on the host cell type.
AQP9 is a member of the AQPs family, which consists of 13
distinct small hydrophobic membrane proteins with
predominant roles in trans-cellular water transport in response
to osmotic gradients (Verkman, 2005). Among the aquaporins,
AQPs 3, 7, 9 and 10, referred to as aquaglyceroporins, also
transport glycerol and other small uncharged solutes (Verkman,
2005). Human AQP9 is widely expressed in the liver but also in
other tissues, including the lung, spleen and leukocytes, whereas
rodent AQP9 has mainly been found at the basolateral
hepatocyte plasma membrane facing the sinusoids (Huebert
et al., 2002; Mazzone et al., 2006) and in a less abundant
manner in other tissues, such as the testis, epididymis, spleen,













P. falciparum AQP9-dependent no infection no infection infection (role of AQP9 not tested) no infection
P. yoelii AQP9-independent no infection AQP9-independent infection (role of AQP9 not tested) AQP9-independent
P. berghei AQP9-dependent AQP9-independent AQP9-independent AQP9-dependent AQP9-dependent
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brain and lung (Ishibashi et al., 1998; Tsukaguchi et al., 1998;
Elkjaer et al., 2000). By regulating water entry or entry of other
small uncharged solutes and interacting with cytoskeleton
elements and signalling cascades, the AQPs can influence cell
morphology, volume, motility and migration (Saadoun et al.,
2005; Holm et al., 2016). Therefore, they are considered potential
therapeutic targets (Saadoun et al., 2005).
The results of our gene silencing experiments demonstrate
that AQP9 expression is required for P. falciparum sporozoite
infection of human hepatocytes, and this requirement appears to
be of the same order of magnitude as it is for CD81, which thus
far is the only hepatocyte surface molecule known to be strictly
required for P. falciparum sporozoite infectivity (Silvie et al.,
2003). Moreover, overexpression of AQP9, as well as of CD81, in
human hepatocytes led to increased P. falciparum infection.
From our previous studies on CD81 (Silvie et al., 2003) and
the current results presented in this paper, one can conclude that
P. falciparum require both CD81 and AQP9 to invade
hepatocytes as the invasion is drastically hampered in the
absence of one or other. There are two arguments that support
this conclusion. First, diminishing expression levels of one does
not impact on the other one. Second, the reduction in hepatocyte
infectivity observed with the inhibition of the expression of either
protein was proportional to its inhibition level, as none is able to
compensate for silencing of the other, suggesting that these two
proteins are operating independently and/or sequentially. While
not tested here, it would be interesting to test whether
simultaneous silencing of both AQP9 and CD81 proteins could
result in a complete invasion-inhibition.
Additional experiments using the rodent parasites P. yoelii
and P. berghei showed that the requirement for AQP9 varies with
the species of the parasite and of the host cell. Thus, invasion of
P. berghei sporozoites was more dependent on the presence of
AQP9 than invasion of P. yoelii sporozoite in murine
hepatocytes, and this effect was more pronounced when
human hepatocytes were used. These findings differ from those
obtained for CD81 dependence (Silvie et al., 2007). Indeed, when
human hepatocytes are used, P. yoelii invasion is strictly
dependent on CD81 but only poorly dependent on AQP9,
whereas for P. berghei, invasion is mainly dependent on AQP9,
at least in human liver cells that express this protein, as it is on
CD81. It should be noted that P. berghei is strictly CD81-
dependent for invasion of the mouse cell line Hepa 1.6 but
CD81-independent when human hepatoma cell lines are used
(Silvie et al., 2007).
Taken together, our results showed that AQP9 and CD81 are
individually required for Plasmodium sporozoite infection, but
that neither is able to compensate for the absence of the other.
Moreover, the species specificity for P. falciparum and P. berghei,
with a lesser impact on P. yoelii, suggest a distinct role for AQP9
to the functions of previously described CD81 or SR-BI (Silvie
et al., 2003; Yalaoui et al., 2008a; Risco-Castillo et al., 2014;
Manzoni et al., 2017), probably acting downstream to the events
requiring both these host proteins. Furthermore, our findings
strengthen previous observations that sporozoite entry into liver
cells is a complex phenomenon and suggest that extrapolation of
results obtained with rodent models to human parasites should
be carried out with caution. This complexity is consistent with
the general view that entry of intracellular pathogens relies on
plastic and dynamic interactions between various molecules at
the cell surfaces of the pathogen and host, as illustrated for HIV,
HCV, and P. falciparum merozoites (Cosset and Lavillette, 2011;
Bartholdson et al., 2013) and for the role of CD81, SR-BI and
CD9P-1 in hepatocyte invasion by Plasmodium sporozoites
(Yalaoui et al., 2008a; Charrin et al., 2009).
Our experiments with human and rodent parasites showed
that AQP9 plays a crucial role in sporozoite invasion but not in
the cell traversal that precedes it. Similar results were reported for
CD81, which was also found to not be required for migration of
P. falciparum and P. yoelii sporozoites through cells (Silvie et al.,
2003). Internalization of the Plasmodium sporozoite and the
associated PVM formation through invagination of the host cell
plasma membrane involves a series of finely orchestrated events,
including gliding motility, moving junction formation, and
penetration (Dundas et al., 2019). Several studies have shown
that this invasion process, as is the case in other Apicomplexa
parasites, requires not only the parasite’s actin-myosin motor but
also membrane reorganization and de novo polymerization of
host actin at the entry site for anchoring the junction on which
the parasite pulls to penetrate the host cell (Gonzalez et al., 2009;
Gomes-Santos et al., 2012; Gaji et al., 2013). Interestingly,
previous studies have shown that AQP9 plays a major role in
processes involving dynamic membrane reorganization and
actin polymerization (Loitto et al., 2002; Loitto et al., 2007).
More importantly, studies of AQP9 inhibition have shown that it
promotes cell membrane protrusions through its water transport
function. It has been proposed that AQP9-induced water influx
results in a pressure-driven forward push of the membrane,
creating a gap that allows diffusion and polymerization of actin
monomers (Loitto et al., 2009; Karlsson et al., 2013). In our
study, the inhibitory effect observed with phloretin strongly
suggests an important role for the transport of water, and
possibly of other small molecules, in liver cell invasion by
Plasmodium sporozoites. Although it is not clear how AQP9
functions to promote sporozoite invasion into hepatocytes, one
could speculate that AQP9 might play an indirect role through
actin polymerization, possibly through its water transport
function. Interestingly, a similar mechanism has been reported
for Cryptosporidium parvum, another intracellular apicomplexan
parasite, in which the host aquaporin AQP1 has been shown to
be crucial for entry of the parasite into cholangiocytes (Chen
et al., 2005). More specifically, it was shown that AQP1 mediates
the localized water influx that leads to the increase in cell volume
and actin polymerization accompanying the membrane
protrusion that allows C. parvum entry and PVM formation
(Chen et al., 2005). Collectively, these data support a model in
which AQP9, through its water permeation function and
possibly permeation of other small molecules, induces the
membrane reorganization and actin polymerization, likely at
the entry site, required to permit invagination of the PVM and
entry of the sporozoite. Additional studies will be necessary to
confirm this hypothesis.
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In conclusion, the present study demonstrates that the host
protein AQP9 is involved in entry of P. falciparum (and of P.
berghei) sporozoites into hepatocytes and suggests that this
process may involve water transport and possibly other small
molecules. Our findings also suggest that P. falciparum
sporozoites are able to highjack hepatocyte membrane
machinery to achieve internalization into the parasitophorous
vacuole. Collectively, our data provide new insights into the
complex cellular process required for Plasmodium infection of
liver cells and may assist in the development of host factor-
directed antimalarial therapies.
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